M&A
confidence high
sentiment positive
materiality 0.65
Eton Pharmaceuticals acquires U.S. rights to Amglidia (glyburide oral suspension) for neonatal diabetes
Eton Pharmaceuticals, Inc.
- No upfront payment; up to $2.35M in milestone payments plus 14% royalty on net sales.
- Amglidia approved by EMA in 2018, has U.S. FDA Orphan Drug Designation.
- Targets neonatal diabetes, a rare condition affecting ~300 U.S. patients with no FDA-approved oral treatment.
- Eton plans FDA meeting in Q1 2025 and expects NDA submission in 2026.
- Eton can terminate within 30 days of FDA meeting minutes without milestone liability.